Interleukin-33 Mediates Cardiomyopathy After Acute Kidney Injury by Signaling to Cardiomyocytes
Circulation · 2023
DOI: 10.1161/circulationaha.122.063014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, 2023. Verfasst von Nans Florens und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Cincinnati Children's Hospital Medical Center, OH (N.F., R.K.K., V.R.-M., S.-C.L., V.P., J.D.M.). Hauptthemen laut MEDLINE: Acute Kidney Injury, Cardiomyopathies, Interleukin-33, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Background
Acute kidney injury (AKI) is a short-term life-threatening condition that, if survived, can lead to renal insufficiency and development of chronic kidney disease. The pathogenesis of AKI and chronic kidney disease involves direct effects on the heart and the development of hypertrophy and cardiomyopathy.
Methods
We used mouse models of ischemia/reperfusion AKI and unilateral ureteral obstruction to investigate the role of IL-33 (interleukin-33) and its receptor-encoding gene Il1rl1 (also called ST2L [suppression of tumorigenicity 2]) in cardiac remodeling after AKI. Mice with cell type–specific genetic disruption of the IL-33/ST2L axis were used, and IL-33 monoclonal antibody, adeno-associated virus encoding IL-33 or ST2L, and recombinant IL-33, as well.
Results
Mice deficient in Il33 were refractory to cardiomyopathy associated with 2 models of kidney injury. Treatment of mice with monoclonal IL-33 antibody also protected the heart after AKI. Moreover, overexpression of IL-33 or injection of recombinant IL-33 induced cardiac hypertrophy or cardiomyopathy, but not in mice lacking Il1rl1 . AKI-induced cardiomyopathy was also reduced in mice with cardiac myocyte–specific deletion of Il1rl1 but not in endothelial cell- or fibroblast-specific deletion of Il1rl1 . Last, overexpression of the ST2L receptor in cardiac myocytes recapitulated induction of cardiac hypertrophy.
Conclusions
These results indicate that IL-33 released from the kidney during AKI underlies cardiorenal syndrome by directly signaling to cardiac myocytes, suggesting that antagonism of IL-33/ST2 axis would be cardioprotective in patients with kidney disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, OH (N.F., R.K.K., V.R.-M., S.-C.L., V.P., J.D.M.).
- Department of Pediatrics, the University of Cincinnati, OH (J.D.M.).
ORCID-Profile: Nans Florens, Jeffery D Molkentin
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Florens, N., Kasam, R. K., Rudman-Melnick, V., Lin, S. C., Prasad, V., & Molkentin, J. D. (2023). Interleukin-33 Mediates Cardiomyopathy After Acute Kidney Injury by Signaling to Cardiomyocytes. Circulation. https://doi.org/10.1161/circulationaha.122.063014
Vancouver
Florens N, Kasam RK, Rudman-Melnick V, Lin SC, Prasad V, Molkentin JD. Interleukin-33 Mediates Cardiomyopathy After Acute Kidney Injury by Signaling to Cardiomyocytes. Circulation. 2023. doi:10.1161/circulationaha.122.063014
BibTeX
@article{Florens2023,
author = {Florens, Nans and Kasam, Rajesh K and Rudman-Melnick, Valeria and Lin, Suh-Chin and Prasad, Vikram and Molkentin, Jeffery D},
title = {Interleukin-33 Mediates Cardiomyopathy After Acute Kidney Injury by Signaling to Cardiomyocytes},
journal = {Circulation},
year = {2023},
doi = {10.1161/circulationaha.122.063014}
}
EUVIMED